SEC Company Response from Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — May 20, 2005

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: May 20, 2005 · CIK: 0001006281 · Accession: 0001006281-05-000009

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

May 18, 2005

Author

Accounting Officer)

Form

CORRESP

Company

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)

Letter

<PAGE> May 18, 2005 Thomas Flinn, Staff Accountant Division of Corporation Finance United States Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549

Re: Orthodontix, Inc. (the "Company") Form 8-K filed May 13, 2005 File No. 0-27836

Dear Mr. Flinn:

In response to your letter of May 17, 2005, the Company has today filed an amended Form 8-K to provide additional disclosure.

This letter will confirm that the Company acknowledges its responsibility for the adequacy and accuracy of the disclosure in Company filings. The Company also acknowledges that staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filing. The Company further acknowledges that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
Alan Jay Weisberg
Acting Chief Financial Officer
(Principal Financial and
Accounting Officer)

Show Raw Text

<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
<PAGE>

May 18, 2005

Thomas Flinn, Staff Accountant
Division of Corporation Finance
United States Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

     Re:  Orthodontix, Inc. (the "Company")
          Form 8-K filed May 13, 2005
          File No. 0-27836

Dear Mr. Flinn:

     In response to your letter of May 17, 2005, the Company has
today filed an amended Form 8-K to provide additional disclosure.

     This letter will confirm that the Company acknowledges its
responsibility for the adequacy and accuracy of the disclosure in
Company filings.  The Company also acknowledges that staff
comments or changes to disclosure in response to staff comments
in the filings reviewed by the staff do not foreclose the
Commission from taking any action with respect to the filing.
The Company further acknowledges that the Company may not assert
staff comments as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the
United States.

                                   Very truly yours,

                                   Alan Jay Weisberg
                                   Acting Chief Financial Officer
                                   (Principal Financial and
                                   Accounting Officer)

</TEXT>
</DOCUMENT>

SecProbe.io